F-CCL27 CAR-T

F-CCL27 CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target the chemokine receptor CCR10, which is highly expressed on multiple myeloma (MM) tumor cells. Developed by researchers at the University of California, San Francisco (UCSF), this therapy utilizes a structure-guided mutant of the natural ligand CCL27 as the antigen-binding domain. Specifically, the binder incorporates a single phenylalanine (F) amino acid addition at the N-terminus of the wild-type CCL27 sequence, which enhances binding affinity to CCR10 compared to the native ligand. In preclinical studies, F-CCL27 CAR-T demonstrated potent cytotoxicity against CCR10-expressing myeloma cell lines and primary patient samples, showing efficacy comparable to anti-BCMA CAR-T therapies. It is intended as a potential treatment for patients with relapsed or refractory multiple myeloma, including those who have failed BCMA-targeted therapies.

Other names

phenylalanine-CCL27 CAR-Tphenylalanine-CCL-27 CAR-Tphenylalanine-CCL 27 CAR-Tanti-CCR10 CAR-Tanti-CCR-10 CAR-Tanti-CCR 10 CAR-TF-CCL27-based CAR-TF-CCL-27-based CAR-TF-CCL 27-based CAR-T